Acepodia, Inc. (TPEX: 6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.50
-0.50 (-2.08%)
Sep 10, 2024, 2:55 PM CST
-26.33%
Market Cap 13.39B
Revenue (ttm) 16.90M
Net Income (ttm) -379.78M
Shares Out 569.64M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 613,529
Open 23.90
Previous Close 24.00
Day's Range 23.30 - 24.00
52-Week Range 20.90 - 40.40
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. It develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial. Acepodia Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Sonny Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.